Adbry/Adtralza Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Adbry/Adtralza market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to FDA approval, rising acceptance among dermatologists, regulatory advancements, expansion into new markets, and the increasing demand for biologic treatments.

Market growth during the forecast period is expected to be driven by the rising prevalence of atopic dermatitis, increased awareness and diagnosis, innovative delivery systems, expansion into emerging markets, and a growing focus on personalized medicine. Key trends in the forecast period include higher adoption rates, emphasis on real-world evidence, regulatory approvals for new indications, a shift toward personalized medicine, and evolving dynamics within the competitive landscape.

The growing prevalence of atopic dermatitis is expected to drive the growth of the adbry/adtralza market. Atopic dermatitis, also known as eczema, is a chronic inflammatory skin condition characterized by intense itching, redness, and irritation. Factors such as increased air pollution, urbanization, changes in childhood skincare practices, and genetic predispositions contribute to the rising prevalence of the condition. Adbry/Adtralza, a monoclonal antibody that targets the interleukin-13 (IL-13) pathway, helps manage atopic dermatitis by reducing inflammation and immune system overactivity, easing symptoms like itching, redness, and irritation in patients with moderate-to-severe forms of the disease. For example, in December 2023, the National Library of Medicine (NLM) reported that the global prevalence of atopic dermatitis is estimated at 2.6%, affecting approximately 204.05 million people worldwide, with around 101.27 million adults and 102.78 million children diagnosed with the condition. Thus, the growing prevalence of atopic dermatitis is driving the adbry/adtralza market.

The increase in healthcare expenditure is expected to drive the growth of the adbry/adtralza market. Healthcare expenditure refers to the total spending on healthcare services and related activities within a specific period, usually annually. It plays a crucial role in enabling the availability and accessibility of innovative treatments such as Adbry (also known as Adtralza). Increased spending on healthcare systems allows for the coverage and distribution of advanced biologics for managing conditions like moderate-to-severe atopic dermatitis, improving patient outcomes and expanding access to essential therapies. For instance, in May 2024, the Office for National Statistics in the UK reported that healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of 0.9% in 2022. Additionally, long-term health and social care expenditure increased by 2.8% in real terms in 2022. Therefore, rising healthcare expenditure is driving the growth of the adbry/adtralza market.

A key trend in the adbry/adtralza market is the focus on developing biologic treatments specifically designed to inhibit interleukin-13 (IL-13) for better therapeutic outcomes in patients with atopic dermatitis. Biologic treatments use biologically derived substances, such as monoclonal antibodies, proteins, or vaccines, to target specific components of the immune system or cellular processes involved in diseases, offering more targeted and often more effective treatment for conditions like autoimmune disorders, cancer, and chronic inflammatory diseases. For example, in December 2023, Leo Pharma, a Denmark-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) expanded the approval of Adbry (tralokinumab-ldrm) to include pediatric patients aged 12 to 17 years with moderate-to-severe atopic dermatitis (AD). This made Adbry the first and only biologic designed specifically to inhibit interleukin-13 (IL-13), a key cytokine involved in the inflammatory processes of atopic dermatitis.

The key players operating in the adbry/adtralza market is LEO Pharma Inc.

North America was the largest region in the adbry/adtralza market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in adbry/adtralza report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the adbry/adtralza market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Adbry (also known as Adtralza) is a monoclonal antibody treatment for moderate to severe eczema (atopic dermatitis) in adults and children aged 6 years and older. It works by targeting interleukin-13 (IL-13), a protein involved in the inflammatory process of eczema. By inhibiting IL-13, Adbry/Adtralza helps reduce inflammation, itching, and rashes on the skin.

The primary use of adbry/adtralza is for treating atopic dermatitis, along with other dermatological conditions. Atopic dermatitis (AD) is a chronic skin disorder marked by itchy, inflamed skin that can cause significant discomfort and disrupt daily activities. This medication is distributed through multiple channels, including hospitals, clinics, retail and specialty pharmacies, and is used by various patient groups, such as adults and the elderly.

The adbry/adtralza market research report is one of a series of new reports that provides adbry/adtralza market statistics, including adbry/adtralza industry global market size, regional shares, competitors with a adbry/adtralza market share, detailed adbry/adtralza market segments, market trends, and opportunities, and any further data you may need to thrive in the adbry/adtralza industry. This adbry/adtralza market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The adbry/adtralza market consists of sales of adbry (Tralokinumab-ldrm), adtralza (Tralokinumab), delgocitinib, TMB-001, and fucidin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.